Skip Ribbon Commands
Skip to main content

Prof Chow Kah Hoe Pierce

Prof Chow Kah Hoe Pierce

MBBS, M Med (Surg), FRCS (Edin), FAMS (Gen Surg), PhD

Senior Consultant

National Cancer Centre Singapore

Specialty: Hepato-pancreato-biliary and Transplant Surgery

Sub-specialties: Hepatobiliary and Pancreatic Surgery

Conditions Treated by this Doctor:
Liver Cancer.

Clinical Appointments

  • Senior Consultant Hepato-pancreato-biliary and Transplant Surgery Singapore General HospitalSingapore General Hospital
  • Senior Consultant Division of Surgical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Professor and Program Director, PhD Programme in Clinical Sciences, Duke-NUS Medical School
  • Academic Vice Chair (Research), Academic Clinical Programme for Surgery (SURG ACP)


Professor Pierce Chow is Senior Consultant and Co-Director (Surgical) of the Comprehensive Liver Cancer Clinic at the National Cancer Centre Singapore, Senior Consultant Surgeon in Hepato-pancreato-biliary and Transplant Surgery at the Singapore General Hospital. He is concurrently Professor and Course Director at the Duke-NUS Medical School Singapore and Adjunct Faculty at the Genome Institute of Singapore.  Prof Chow was the Chapter of Surgeon’s Gold Medallist at the conjoint Royal College of Surgeons of Edinburgh/M.Med (Surgery) examination in 1994 and subsequently completed a clinical fellowship in Liver Transplantation at the Queensland Liver Transplant Service. In 1995, he was recipient of the Young Surgeon’s Award of the Academy of Medicine Singapore for his research into the patho-physiology of liver blood flow and regeneration.  
In addition to managing a busy HPB surgical oncology service, Prof Chow has researched extensively on hepatocellular carcinoma (HCC). He is actively involved in clinical trials on novel therapies and leads collaborative multi-disciplinary research on intra-tumoral genomic, immunomic and metabolomic heterogeneity in HCC and their applications to precision medicine. He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group in 1997 and has been the protocol chair of 7 prospective multi-national trials including the SIRveNIB trial which closed in 2016. In 2005 he led the multi-disciplinary research that developed BrachySil® (now OncoSil®) and the subsequent first-in-man trial. In 2012 the National Medical Research Council Singapore conferred him the National Outstanding Clinician-Scientist Award for improving clinical outcomes of patients with his research on Liver Cancer. Prof Chow was awarded the NMRC Translational-Clinical Research Grant for the Flagship Program in Liver Cancer in 2016 and has commenced the multi-national PLANET study (Precision Medicine in Liver Cancer Asia-Pacific Network). In 2017, Prof Chow further received funding from NMRC Clinician Scientist Award (Senior Investigator) to further establish a genomics-immunomics-phenomics platform under the Flagship Program in Liver Cancer and BMRC for the multi-institutional PuRPOSE Program to develop a patient-specific diagnostic and predictive platform to improve treatment of liver cancer. His latest appointment sees him as the Co-Program Director of the PuRPOSE program in collaboration with Samsung Medical Center.


  • PhD, National University of Singapore 
  • FAMS (General Surgery), Academy of Medicine, Singapore 
  • USMLE, United States Medical Licensing Examination 1 and 2 
  • Certificate of Specialist Accreditation, Singapore Medical Council 
  • FRCS (Edinburgh) 
  • M.Med. (Surgery), National University of Singapore 
  • MBBS, National University of Singapore 

Professional Appointments and Committee Memberships

  • Founding President, College of Clinician Scientists Singapore, Academy of Medicine Singapore 
  • Council, Asia-Pacific Primary Liver Cancer Expert Association 
  • Council, Academy of Medicine Singapore  
  • Protocol Chair, Asia-Pacific Hepatocellular Carcinoma Trials Group 
  • Member, Research Training Review Panel, Specialists Accreditation Board, Ministry of Health 
  • Member, Research Committee, Specialists Accreditation Board, Ministry of Health
  • Member, Complaints Panel, Singapore Medical Council 
  • Member, American Society of Clinical Oncology 
  • Member, Singapore Society of Oncology
  • Member, International Hepato-Pancreato-Biliary Association Scientific Committee 
  • Member, Asia-Pacific Hepato-Pancreato-Biliary Association
  • Founding member, International Liver Cancer Association (ILCA)
  • Member, Australasian Gastrointestinal Trials Group Trials Group
  • Fellow, The Royal College of Surgeons of Edinburgh (RCSEd)
  • Fellow, Singapore Medical Association


  • National Day Awards, Long Service Medal, 2016
  • SingHealth Duke-NUS Research Team Award, 2nd Prize, 2015
  • Outstanding Faculty for Engagement Award (Normal Body), Duke-NUS Medical School, 2013
  • Outstanding Faculty for Advocacy Award (Normal Body), Duke-NUS Medical School, 2012
  • Outstanding Faculty for Engagement Award (Surgery), Duke-NUS, 2012
  • National Outstanding Clinician Scientist Award, NMRC, 2012 
  • Singapore Health Quality Service Award, Silver, 2011
  • Pioneer Award, Duke-NUS Medical School, 2011
  • Service With A Heart Award, Singapore General Hospital, 2010
  • Senior Investigator Clinician Scientist Award, National Medical Research Council, 2010
  • Outstanding Educator Award, Duke-NUS Medical School, 2009, 2010 
  • Excellent Publication Award, SingHealth (Singapore General Hospital), 2006
  • Excellent Service Award (Gold), Healthcare. Spring Singapore, 2004
  • SARS Courage Medal. Government of Singapore, 2003
  • Sir James Fraser Fellow. Royal College of Surgeons of Edinburgh, 2002
  • HMDP Clinical Fellowship in HPB Surgery and Liver Transplantation, 1999
  • Seah Cheng Siang Prize GE Society of Singapore. Best original research, 1997
  • NMRC - Singapore Totalisator Board Medical Research Fellowship, 1997
  • Young Surgeon’s Award, Academy of Medicine, Singapore, 1995
  • NMRC - Kwek Hong Png Medical Research Fellowship, 1995
  • Chapter of Surgeon’s Gold Medal Conjoint M.Med /FRCS (Edinburgh), 1994

Research Interests

  • Genomics, immunomics and metabolomics as applied to Precision Medicine in Hepatocellular Carcinoma 
  • Clinical Trials and longitudinal studies in Hepatocellular Carcinoma 
  • Meta-analysis, Systemic Review and Health Services Outcomes Research in Hepatocellular Carcinoma  
  • Brachytherapy and Selective Internal Radiation Therapy 
  • Patient tumour-explant xenografts in experimental oncology


  • Venerito, Marino, Pech, Maciej, Canbay, Ali, Donghia, Rossella, Guerra, Vito, Chatellier, Gilles, Pereira, Helena, Gandhi, Mihir, Chow, Pierce K. H., Vilgrain, Valerie, Malfertheiner, Peter, Ricke, Jens & Leandro, Gioacchino. 2020. NEMESIS: Non-inferiority, Individual Patient Meta-analysis of Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres versus Sorafenib in Advanced Hepatocellular Carcinoma. Journal of Nuclear Medicine May 1, 2020 jnumed.120.242933, doi: 10.2967/jnumed.120.242933
  • Ding, Z., Ericksen, R, Escande-Beillard, N., Lee, Q.Y, Loh A., Denil, S., Steckel, M., Andrea Haegebarth, A., Ho, S.W., Chow, P.K., Toh, H.C., Reversade, B., Gruenewald, S., Han, W. (2020). Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. Journal of Hepatology, Volume 72, Issue 4, 2020, Pages 725-735, ISSN 0168-8278,
  • Huynh, H., Lee, L.Y., Goh, K.Y., Ong, R., Hao, H.X., Huang, A., Wang, Y., Graus, P.D., Chow, P., and Chung, A. (2019). Infigratinib mediates vascular normalization, impairs metastasis, and improves chemotherapy in hepatocellular carcinoma. Hepatology 69(3): 943-958. doi: 10.1002/hep.30481.
  • Zhao, Y., Shuen, T.W.H., Toh, T.B., Chan, X.Y., Liu, M., Tan, S.Y., Fan, Y., Yang, H., Lyer, S.G., Bonney, G.K., Loh, E., Chang, K.T.E., Tan, T.C., Zhai, W., Chan, J.K.Y., Chow, E.K., Chee, C.E., Lee, G.H., Dan, Y.Y., Chow, P.K., Toh, H.C., Lim, S.G., and Chen, Q. (2018). Development of a New Patient-Derived Xenograft Humanised Mouse Model to Study Human-Specific Tumour Microenvironment and Immunotherapy. Gut. pii: gutjnl-2017-315201. doi: 10.1136/gutjnl-2017-315201.
  • Lim, C.J., Lee, Y.H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T.K.H., Yeong, J., Toh, H.C., Lee, S.Y., Chan, C.Y., Goh, B.K., Chung, A., Heikenwalder, M., Ng, I.O., Chow, P., Albani, S., and Chew, V. (2018). Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut. 10.1136/gutjnl-2018-316510.
  • Chow, P.K.H., Gandhi, M., Tan, S.B., Khin, M.W., Khasbazar, A., Ong, J., Choo, S.P., Cheow, P.C., Chotipanich, C., Lim, K., Lesmana, L.A., Manuaba, T.W., Yoong, B.K., Raj, A., Law, C.S., Cua, I.H.Y., Lobo, R.R., Teh, C.S.C., Kim, Y.H., Jong, Y.W., Han, H.S., Bae, S.H., Yoon, H.K., Lee, R.C., Hung, C.F., Peng, C.Y., Liang, P.C., Bartlett, A., Kok, K.Y.Y., Thng, C.H., Low, A.S., Goh, A.S.W., Tay, K.H., Lo, R.H.G., Goh, B.K.P., Ng, D.C.E., Lekurwale, G., Liew, W.M., Gebski, V., Mak, K.S.W., Soo, K.C., and Asia-Pacific Hepatocellular Carcinoma Trials, G. (2018). Sirvenib: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients with Hepatocellular Carcinoma. J Clin Oncol 36, 1913-1921. 10.1200/JCO.2017.76.0892.
  • Chew, V., Lee, Y.H., Pan, L., Nasir, N.J.M., Lim, C.J., Chua, C., Lai, L., Hazirah, S.N., Lim, T.K.H., Goh, B.K.P., Chung, A., Lo, R.H.G., Ng, D., Filarca, R.L.F, Albani, S., and Chow, P.K.H. (2018). Immune Activation Underlies a Sustained Clinical Response to Yttrium-90 Radioembolisation in Hepatocellular Carcinoma. Gut. pii: gutjnl-2017-315485. doi: 10.1136/gutjnl-2017-315485.
  • Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V: Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 2017, 66(2):342-351.
  • Zhai, W., Lim, T.K., Zhang, T., Phang, S.T., Tiang, Z., Guan, P., Ng, M.H., Lim, J.Q., Yao, F., Li, Z., Ng, P.Y., Yan, J., Goh, B.K., Chung, A.Y., Choo, S.P., Khor, C.C., Soon, W.W., Sung, K.W., Foo, R.S., and Chow, P.K. (2017). The Spatial Organization of Intra-Tumour Heterogeneity and Evolutionary Trajectories of Metastases in Hepatocellular Carcinoma. Nat Commun 8, 4565. 10.1038/ncomms14565.
  • Chan-On, W., Nairismagi, M.L., Ong, C.K., Lim, W.K., Dima, S., Pairojkul, C., Lim, K.H., McPherson, J.R., Cutcutache, I., Heng, H.L., Ooi, L., Chung, A., Chow, P., Cheow, P.C., Lee, S.Y., Choo, S.P., Tan, I.B., Duda, D., Nastase, A., Myint, S.S., Wong, B.H., Gan, A., Rajasegaran, V., Ng, C.C., Nagarajan, S., Jusakul, A., Zhang, S., Vohra, P., Yu, W., Huang, D., Sithithaworn, P., Yongvanit, P., Wongkham, S., Khuntikeo, N., Bhudhisawasdi, V., Popescu, I., Rozen, S.G., Tan, P., and Teh, B.T. (2013). Exome Sequencing Identifies Distinct Mutational Patterns in Liver Fluke-Related and Non-Infection-Related Bile Duct Cancers. Nat Genet 45, 1474-1478. 10.1038/ng.2806.

Research Trials

  • Decoding global gene expressions in Liver Cancer through Deep Learning and standard-of-care
  • The Utility of LiverMultiScan Analysis of MRI scans in Patients with Hepatocellular Carcinoma for Improved Prognostication and as an Aid to the Selection of Therapy
  • Decoding global gene expressions in Liver Cancer through Deep Learning and standard-of-care
  • An Integrative Genomic Approach for Molecular Classification of Hepatocellular Carcinoma (HCC) and their correlation with the Clinical Outcomes
  • An integrated multi-omics study on primary liver cancer and patients at risk of liver cancer
  • Hepatocellular Carcinoma (HCC) Registry in Asia (AHCC08)
  • Precision Medicine in Liver Cancer across an Asia-Pacific Network (AHCC07)
  • A Patient-Specific Diagnostic and Predictive Platform for Precision Medicine in HCC
  • Post-SIR Spheres® surgery study (P4S): a retrospective analysis in patients with primary liver tumours or secondary hepatic metastases 
  • Phase III Multi‐Centre Open‐Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib In Locally Advanced Hepatocellular Carcinoma (SIRveNIB) (AHCC06)
  • Study of SIR-Spheres plus Sorafenib as 1st Line Treatment for Non-Resectable Primary Hepatocellular Carcinoma (AHCC05)
  • A Study of the Safety Profile of Three Escalating Radioactivity Levels of 32P BioSilicon Delivered with the SIMPL Needle as Intratumoural Implantations in Patients With Unresectable Hepatocellular Carcinoma (AHCC04)
  • Randomized Phase III Trial to determine the Effectiveness of Megestrol Acetate in treating Patients who have Liver Cancer that cannot be removed by surgery (AHCC02)
  • Phase III Randomized Study of High Dose Tamoxifen versus Placebo in Patients with Inoperable Hepatocellular Carcinoma (AHCC01)